Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 680.65 INR
Change Today 0.00 / 0.00%
Volume 0.0
As of 7:05 AM 07/3/15 All times are local (Market data is delayed by at least 15 minutes).

alembic pharmaceuticals ltd (ALPM) Snapshot

Open
662.50
Previous Close
672.55
Day High
687.00
Day Low
662.50
52 Week High
06/26/15 - 698.80
52 Week Low
07/9/14 - 298.25
Market Cap
128.3B
Average Volume 10 Days
329.1K
EPS TTM
15.01
Shares Outstanding
188.5M
EX-Date
07/22/15
P/E TM
45.3x
Dividend
3.50
Dividend Yield
0.44%
Current Stock Chart for ALEMBIC PHARMACEUTICALS LTD (ALPM)

Related News

No related news articles were found.

alembic pharmaceuticals ltd (ALPM) Related Businessweek News

No Related Businessweek News Found

alembic pharmaceuticals ltd (ALPM) Details

Alembic Pharmaceuticals Limited, an integrated pharmaceutical company, develops, manufactures, and markets pharmaceutical products, pharmaceutical substances, and intermediates in India and internationally. The company offers active pharmaceutical ingredients; and bulk pharma chemicals, including phosgene gas and phosgene based specialty chemicals/intermediates for use in pesticides, pharmaceuticals, dyes, plastics, perfumeries, etc., as well as drug intermediates, fine chemicals, and specialty chemicals. It also provides contract manufacturing and custom synthesis services; finished dosage formulations for various therapeutic areas comprising antibiotics and antibacterial, anti-diabetic, antihistamines, cardiovascular, cough and cold, dermatological, gastroenterological, gynecological, opthalmological, orthopaedic, urology, and herbal nutraceuticals; and veterinary and generic products. In addition, the company offers contract/collaborated research services. Alembic Pharmaceuticals Limited was founded in 1907 and is headquartered in Vadodara, India.

Founded in 1907

alembic pharmaceuticals ltd (ALPM) Top Compensated Officers

Chairman, Managing Director and Chairman of C...
Total Annual Compensation: 44.9M
Joint Managing Director, President of Branded...
Total Annual Compensation: 40.0M
Joint Managing Director, President of Interna...
Total Annual Compensation: 37.4M
Chief Financial Officer, Director of Finance ...
Total Annual Compensation: 22.5M
Vice President of Finance, Compliance Officer...
Total Annual Compensation: 6.9M
Compensation as of Fiscal Year 2015.

alembic pharmaceuticals ltd (ALPM) Key Developments

Breckenridge Pharmaceutical, Inc. and Alembic Pharmaceuticals Limited Get Final ANDA Approval for Desvenlafaxine XR Tablets

Breckenridge Pharmaceutical, Inc. announced that Breckenridge and Alembic Pharmaceuticals Limited were granted final approval for their ANDA desvenlafaxine succinate extended-release tablets 50 mg and 100 mg, a generic version of Pristiq by Pfizer Inc. Breckenridge and Alembic filed their Paragraph IV ANDA on the first-to-file date and expect to share 180-day exclusivity with other ANDA first filers. Alembic Pharmaceuticals Limited is the sponsor and manufacturer of the ANDA, which will be marketed exclusively by Breckenridge. The Paragraph IV litigation with respect to the ANDA has been settled on terms that are confidential. The settlement includes a license effective prior to the expirations of the patents involved in the litigation. Further announcements will be made prior to product launch. Desvenlafaxine is a prescription drug that is indicated for the treatment of major depressive disorder. Desvenlafaxine is in a class of medications called selective serotonin and norepinephrine reuptake inhibitors (SNRIs). The product will be available in 50 mg and 100 mg tablets. Breckenridge's latest patent challenge for desvenlafaxine succinate extended-release tablets 50 mg and 100 mg highlights its aggressive Paragraph IV strategy. Breckenridge currently has twenty-two ANDAs filed and pending with FDA that contain Paragraph IV patent challenges, and intends to continue that trend in the next several years, focusing on niche and first-to-file Paragraph IV opportunities with certain barriers to entry.

Alembic Pharmaceuticals Ltd Appoints Pranav Amin and Shaunak Amin as Joint Managing Directors, Effective April 27, 2015

Alembic Pharmaceuticals Ltd. has announced that the Board of Directors of the company at its meeting held on April 27, 2015 appointed Mr. Pranav Amin as Joint Managing Director with effect from April 27, 2015 and also appointed Mr. Shaunak Amin as Joint Managing Director with effect from April 27, 2015.

Alembic Pharmaceuticals Limited Recommends Dividend

Alembic Pharmaceuticals Limited announced that the Board of Directors of the company at its meeting held on April 27, 2015 has recommended a dividend of INR 3.50 (175%) per Equity Share of face value of INR 2 each, subject to approval of Shareholders at the ensuing Annual General Meeting.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALPM:IN 680.65 INR +8.10

ALPM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ALPM.
View Industry Companies
 

Industry Analysis

ALPM

Industry Average

Valuation ALPM Industry Range
Price/Earnings 44.5x
Price/Sales 6.1x
Price/Book 14.2x
Price/Cash Flow 38.5x
TEV/Sales 6.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALEMBIC PHARMACEUTICALS LTD, please visit www.alembic-india.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.